FDA Approves Lisraya, the First Oral Targeted Therapy for Dermatomyositis

The FDA has approved Lisraya (brepocitinib) — the first oral, targeted therapy for dermatomyositis, a rare autoimmune disease causing progressive muscle weakness and painful, itchy skin lesions.

Approved August 27, 2026 and developed by Priovant Therapeutics, a Roivant company, the once-daily pill is a TYK2/JAK1 inhibitor that dampens the overactive immune signalling driving the disease.

What dermatomyositis does

It attacks on two fronts simultaneously. Muscle inflammation produces progressive weakness — difficulty climbing stairs, rising from a chair, lifting arms above the head — and in severe cases affects the muscles of swallowing and breathing. Skin involvement produces distinctive rashes that are frequently intensely itchy and disfiguring.

Patients often find the skin disease the harder burden, which is easy to underestimate from outside. Rashes on the face, hands and chest are visible, persistent and socially isolating in a way muscle weakness sometimes is not.

The steroid problem

Until now, patients had no targeted oral option and relied heavily on corticosteroids and broad immunosuppressants.

Corticosteroids work — that is why they persist — and long-term use at meaningful doses causes serious cumulative harm: bone loss and fractures, diabetes, cataracts, weight gain, skin thinning, infection risk, mood disturbance. In a chronic disease, patients frequently end up trading disease damage for treatment damage.

The dilemma is sharper here because steroids themselves cause muscle weakness. In a disease defined by muscle weakness, a clinician can face genuine difficulty distinguishing inadequately treated disease from steroid-induced myopathy — where the correct responses are opposite.

What the trial measured

Approval rests on the Phase 3 VALOR trial, described as the largest dermatomyositis study conducted. Improvement on the myositis Total Improvement Score appeared as early as week 4 and was sustained through 52 weeks.

The headline results are steroid-focused, and deliberately so. 55% of Lisraya patients achieved at least moderate improvement while using minimal or no steroids, versus 30% on placebo. Among those on higher steroid doses at baseline, 45% came off steroids entirely, versus 29% on placebo.

Why steroid-sparing is the right endpoint

Combining disease improvement with steroid reduction into a single measure is more demanding than either alone, and it reflects the actual clinical goal.

Demonstrating improvement while patients remain on high-dose steroids proves little, since the steroids may be doing the work. Demonstrating steroid withdrawal without disease control is worse than useless. The endpoint requires both: patients improving and off the drug causing the collateral damage.

The 45% versus 29% figure for complete steroid discontinuation is the one patients would care about most. Coming off steroids after years is a substantial change in daily life, and the placebo figure of 29% is a reminder that tapering succeeds for some patients regardless — which is exactly why a controlled comparison was needed.

How the drug works

Lisraya inhibits both TYK2 and JAK1, enzymes transmitting signals from inflammatory cytokine receptors into cells. Blocking them interrupts multiple inflammatory pathways at once.

Dual inhibition is a deliberate choice with a trade-off. Selective TYK2 inhibition offers a better safety profile but has proven insufficient in several diseases beyond psoriasis. Adding JAK1 broadens the effect and increases the risk profile — which is precisely what the label reflects.

The boxed warning

As a JAK-inhibitor-class drug, Lisraya carries a boxed warning for serious infections, mortality, cancer, major cardiovascular events and blood clots.

This is a class warning applied across JAK inhibitors following a large safety study in rheumatoid arthritis patients with cardiovascular risk factors, and it is applied broadly rather than being specific to this drug or this disease. It nonetheless represents a serious set of risks requiring discussion with every patient.

The comparison that matters, though, is not against nothing. It is against long-term high-dose corticosteroids, which carry their own substantial and well-documented harms. Neither option is benign, and a drug enabling steroid withdrawal may improve the overall risk position even carrying a boxed warning of its own.

Why it matters

“The approval of Lisraya marks a turning point,” said Harvard’s Dr Ruth Ann Vleugels, citing the first “targeted, once-daily oral medicine” for the disease.

What an oral option changes practically

Route of administration is easy to treat as a convenience question and matters more than that in a rare chronic disease.

The alternatives patients have relied on when steroids failed include intravenous immunoglobulin, which requires infusion sessions lasting hours, repeated regularly, at specialist centres. For someone with muscle weakness that makes travel difficult, and who may already have lost the ability to work, that burden is substantial — and access depends on living within reach of a centre that provides it.

A once-daily tablet removes the infrastructure requirement entirely. It also changes who can realistically be treated: patients in rural areas, patients without reliable transport, and patients whose disease makes travel painful are all better served by a therapy that arrives at a pharmacy. For a condition affecting a small, geographically dispersed population, that is a meaningful expansion of who a treatment can actually reach.

Rare diseases with adequate old treatments attract little development. Dermatomyositis had steroids, which worked well enough that the unmet need was easy to overlook — while patients accumulated damage from the treatment. An effective oral therapy helping patients taper is a meaningful advance in a landscape that had changed little. Regulatory news, not medical advice.